Cargando…
Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives
Classical Hodgkin lymphoma (cHL) has been identified with universal genetic alterations of chromosome 9p24.1, which contains PD-L1/PD-L2 genes. The amplification of 9p24.1 is associated with the increased expression of PD-L1 and PD-L2 on RS cells, which promotes their immune evasion, and subsequentl...
Autores principales: | Lin, Ningjing, Song, Yuqin, Zhu, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369179/ https://www.ncbi.nlm.nih.gov/pubmed/32694896 http://dx.doi.org/10.21147/j.issn.1000-9604.2020.03.03 |
Ejemplares similares
-
Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018) -
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021) -
Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
por: Mazloom, Anita, et al.
Publicado: (2020) -
Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma
por: Apostolidis, John, et al.
Publicado: (2020) -
Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
por: DeCarli, Kathryn, et al.
Publicado: (2022)